Cubist Pharmaceuticals News
Cubist Pharmaceuticals (Nasdaq:CBST) hit a new 52-week high Monday as it is currently trading at $49.94, above its previous 52-week high of $49.86 with 49,619 shares traded as of 9:50 a.m. ET. Average volume has been 760,600 shares over the past 30 days.
For the fifth consecutive year, Cubist Pharmaceuticals, Inc. has been named to the Globe 100 annual list, the Boston Globe’s annual ranking of the 100 top-performing public companies headquartered in Massachusetts.
A Disconnect Between Future Prospects of Drug Candidates Versus Where Share Price is Currently Trading: Portfolio Manager Finny Kuruvilla Discusses the Biotech and Pharmaceutical SectorsMay 16
Gilead presented encouraging data on idelalisib.
Cempra entered into an exclusive license and development agreement with Toyama Chemical for an antibiotic candidate, solithromycin
With the company's pipeline in turmoil, AstraZeneca looks into the acquisition game.